Pivotal data are due soon with the Claudin18.2-targeting ADC sonesitatug vedotin.
ApexOnco Front Page
Recent articles
JSKN027 will become the first ADC with this mechanism to enter human trials.
A new KRAS degrader and PD-1 x Lag3 bispecific have just started phase 1.
Suzhou Zelgen’s DLL3 x DLL3 project looks better than regular T-cell engagers, with caveats.
The company sees an improvement with a Tecvayli/Talvey combo vs either monotherapy.
The players are vying in the CD19 x CD20 Car-T arena.
The Enliven molecule looks competitive against Scemblix, triggering a $200m raise.
INCA033989 looks potent in essential thrombocythemia, but already the opportunity looks tiny.
